Evolus (NASDAQ:EOLS) Shares Up 15.3% – Time to Buy?

Shares of Evolus, Inc. (NASDAQ:EOLS) traded up 15.3% during trading on Thursday . The company traded as high as $14.85 and last traded at $16.44. 203,784 shares changed hands during trading, a decline of 77% from the average session volume of 868,460 shares. The stock had previously closed at $14.26.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on EOLS shares. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Tuesday, January 21st. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Wednesday, January 22nd. Finally, Barclays boosted their price target on Evolus from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, January 27th.

Evolus Trading Up 5.5 %

The stock’s 50-day simple moving average is $11.99 and its two-hundred day simple moving average is $13.95. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The firm has a market capitalization of $952.33 million, a P/E ratio of -16.53 and a beta of 1.33.

Institutional Investors Weigh In On Evolus

A number of institutional investors have recently bought and sold shares of the business. Barclays PLC lifted its position in shares of Evolus by 12.9% in the fourth quarter. Barclays PLC now owns 105,786 shares of the company’s stock valued at $1,167,000 after acquiring an additional 12,124 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Evolus in the 4th quarter worth approximately $575,000. Dynamic Technology Lab Private Ltd lifted its holdings in Evolus by 60.3% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 18,886 shares of the company’s stock worth $208,000 after purchasing an additional 7,103 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Evolus by 41.6% in the 4th quarter. Wells Fargo & Company MN now owns 49,347 shares of the company’s stock worth $545,000 after purchasing an additional 14,506 shares during the period. Finally, ExodusPoint Capital Management LP purchased a new stake in Evolus during the 4th quarter valued at approximately $149,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.